CGEN
What one share of Compugen holds
Biological Products, (No Diagnostic Substances)
We are a clinical-stage therapeutic discovery and development company utilizing Unigen™, our AI/ML powered computational discovery platform, to identify novel drug targets and to develop therapeutics in the field of cancer immunotherapy.
Compugen’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Sales | $0.78 |
|---|---|
| Profit | $0.38 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | $0.34 |
| Cash and investments | $1.06 |
| Book value | $1.09 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.01 | −$0.62 | $0.05 | −$0.44 | — | $1.24 |
| 2017 | — | −$0.72 | $0.01 | −$0.61 | — | $0.57 |
| 2018 | $0.32 | −$0.41 | $0.00 | −$0.24 | — | $0.62 |
| 2019 | — | −$0.43 | $0.00 | −$0.44 | — | $0.56 |
| 2020 | $0.03 | −$0.37 | $0.00 | −$0.36 | — | $1.43 |
| 2021 | $0.07 | −$0.41 | $0.00 | −$0.27 | — | $1.23 |
| 2022 | $0.09 | −$0.39 | $0.01 | −$0.40 | — | $0.90 |
| 2023 | $0.38 | −$0.21 | $0.00 | −$0.41 | — | $0.73 |
| 2024 | $0.31 | −$0.16 | $0.00 | $0.55 | — | $0.61 |
| 2025 | $0.78 | $0.38 | $0.00 | $0.33 | — | $1.09 |